Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases (Q33358665)

26 July 2017

title

Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases (English)

1 reference

26 July 2017

0 references

1 reference

Mario Tiribelli

7

0 references

Michele Baccarani

9

object named as

Michele Baccarani

1 reference

26 July 2017

Francesco Zaja

1

1 reference

26 July 2017

Nicola Vianelli

2

1 reference

26 July 2017

Alessandra Sperotto

3

1 reference

26 July 2017

Francesca Patriarca

4

1 reference

26 July 2017

Monica Tani

5

1 reference

26 July 2017

Luciana Marin

6

1 reference

26 July 2017

Anna Candoni

8

1 reference

26 July 2017

Renato Fanin

10

1 reference

26 July 2017

publication date

1 November 2003

1 reference

26 July 2017

1 reference

26 July 2017

volume

44

1 reference

26 July 2017

issue

11

1 reference

26 July 2017

page(s)

1951-1955

1 reference

Chronic lymphocytic leukemia: new insights into biology and therapy

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000119235

Sensorimotor polyneuropathy associated with chronic lymphocytic leukemia, IgM antigangliosides antibody and human T-cell leukemia virus I infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000119235

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000119235

Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000119235

Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000119235

Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000119235

Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000119235

Rituximab for the treatment of type II mixed cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000119235

Autoimmunity in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000119235

Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000119235

Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000119235

10.1080/1042819031000119235

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference